The invention discloses application of an Fn1-PPARbeta /
delta signal channel related to a cardiac
liver disease. The cardiac
liver disease model is constructed according to the conditions that the liver development of young individuals is delayed due to
heart injury and both adult and young individuals have serious fatty livers. In the model, the Fn1
protein level in the heart and blood is obviously increased compared with the
normal level. Based on a zebra fish heart
ablation means, after heart
ablation injury, the heart specific knock-down Fn1 can lead to reduction of the Fn1
protein level in blood and alleviation of liver development retardation and fat deposition. Through the screening of transcriptomics, the PPARbeta /
delta protein in the liver is found to be a potential downstream
effect factor of Fn1. The liver specific overexpression PPARbeta /
delta protein can significantly relieve abnormal phenotypes such as
liver fat deposition caused by
heart injury, and after the liver specific knock-down PPARbeta / delta protein, the protection effect of knock-down Fn1 on the liver disappears under the condition of
heart injury. Therefore, the Fn1 protein and the PPARbeta / delta protein can be used as targets for preventing and treating the cardiac
liver injury, and are used for preparing medicines for improving the cardiac
liver injury, so that a new way is provided for treating the cardiac
liver disease.